All Stories

  1. Monocarboxylate transporters in physiology and cancer: from fundamentals to clinical translation
  2. Tandem Cyclization–Ring Opening of Chromenylamidines: A Direct Route to Pyrido[2,3‍‐‍ d ]pyrimidin‐4(1 H )‐Ones With Anticancer Activity
  3. Mapping Compounding Medication Errors and Contributing Factors in Hospital Pharmacy: A Scoping Review
  4. Glycolytic Reprogramming in Endometriosis: Biological Basis and Emerging Targets for Disease-Modifying Therapy
  5. Mild and Sustainable Synthesis of Chromene Dimers Through Amidine and Flexible Diamine Linkers
  6. Lactic acid promotes an MDSC-like phenotype via HIF1α stabilization with impact on prognosis in renal cell carcinoma
  7. Gut microbiota metabolites positively impacts chemotherapy effects in colorectal cancer
  8. Rational design of anticancer multidrug nanosystems and their adaptation for glioblastoma treatment
  9. Functional and Mechanistic Insights of 3-Hydroxybutyrate (3-OBA) in Bladder Cancer
  10. Metabolism-targeted therapy in NSCLC – A new theranostics inhalation approach using lactate functionalized and selenium-chrysin loaded nanoparticles (SeChry@PUREG4-LA24)
  11. Multimodal nanoparticles co-delivering bevacizumab and dichloroacetate for dual targeting of neoangiogenesis and hyperglycolysis in glioblastoma treatment
  12. 3-Bromopyruvate boosts the effect of chemotherapy in acute myeloid leukemia by a pro-oxidant mechanism
  13. Exposure to potentially harmful excipients in neonates admitted to intensive care units using compounded medicines
  14. Raman spectroscopy for classification of neoplastic and non-neoplastic CAM colon tumors
  15. Cisplatin-Resistant Urothelial Bladder Cancer Cells Undergo Metabolic Reprogramming beyond the Warburg Effect
  16. Glucose Metabolism as a Potential Therapeutic Target in Cytarabine-Resistant Acute Myeloid Leukemia
  17. Effects of Lactate Transport Inhibition by AZD3965 in Muscle-Invasive Urothelial Bladder Cancer
  18. Optimization of iron-ZIF-8 catalysts for degradation of tartrazine in water by Fenton-like reaction
  19. Sustainable fluorescent dye-faujasite zeolite systems as tools for cancer bioimaging
  20. Extracellular Matrix Collagen I Differentially Regulates the Metabolic Plasticity of Pancreatic Ductal Adenocarcinoma Parenchymal Cell and Cancer Stem Cell
  21. Phenolic Compounds Contribution to Portuguese Propolis Anti-Melanoma Activity
  22. Prognostic Value of Monocarboxylate Transporter 1 Overexpression in Cancer: A Systematic Review
  23. Glucose Metabolism Reprogramming in Bladder Cancer: Hexokinase 2 (HK2) as Prognostic Biomarker and Target for Bladder Cancer Therapy
  24. Immunoexpression profile of hypoxia-inducible factor (HIF) targets in potentially malignant and malignant oral lesions: a pilot study
  25. Targeting Lysosomes in Colorectal Cancer: Exploring the Anticancer Activity of a New Benzo[a]phenoxazine Derivative
  26. 3-Bromopyruvate Suppresses the Malignant Phenotype of Vemurafenib-Resistant Melanoma Cells
  27. Microbiota-Derived Short-Chain Fatty Acids: New Road in Colorectal Cancer Therapy
  28. Selective Cytotoxicity of Portuguese Propolis Ethyl Acetate Fraction towards Renal Cancer Cells
  29. Portuguese Propolis Antitumoral Activity in Melanoma Involves ROS Production and Induction of Apoptosis
  30. In Vitro CRISPR/Cas9 Transfection and Gene-Editing Mediated by Multivalent Cationic Liposome–DNA Complexes
  31. Magnetic Solid Nanoparticles and Their Counterparts: Recent Advances towards Cancer Theranostics
  32. Colon microbiota modulation by dairy-derived diet: new strategy for prevention and treatment of colorectal cancer
  33. In Vivo Anticancer Activity of AZD3965: A Systematic Review
  34. MCT1 Is a New Prognostic Biomarker and Its Therapeutic Inhibition Boosts Response to Temozolomide in Human Glioblastoma
  35. Cancer Cells’ Metabolism Dynamics in Renal Cell Carcinoma Patients’ Outcome: Influence of GLUT-1-Related hsa-miR-144 and hsa-miR-186
  36. Nestin Expression Is Associated with Relapses in Head and Neck Lesions
  37. Disruption of pH Dynamics Suppresses Proliferation and Potentiates Doxorubicin Cytotoxicity in Breast Cancer Cells
  38. Angiogenesis and Chromene-based Antiangiogenic Therapeutic Agents
  39. Modulating chitosan-PLGA nanoparticle properties to design a co-delivery platform for glioblastoma therapy intended for nose-to-brain route
  40. The Role of Diet Related Short-Chain Fatty Acids in Colorectal Cancer Metabolism and Survival: Prevention and Therapeutic Implications
  41. The metabolic landscape of urological cancers: New therapeutic perspectives
  42. Microbes and Cancer: Friends or Faux?
  43. IL-17A and IL-17F orchestrate macrophages to promote lung cancer
  44. Lactate Beyond a Waste Metabolite: Metabolic Affairs and Signaling in Malignancy
  45. A novel strategy for glioblastoma treatment combining alpha-cyano-4-hydroxycinnamic acid with cetuximab using nanotechnology-based delivery systems
  46. Competitive glucose metabolism as a target to boost bladder cancer immunotherapy
  47. Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
  48. Lactate and Lactate Transporters as Key Players in the Maintenance of the Warburg Effect
  49. New horizons on pH regulators as cancer biomarkers and targets for pharmacological intervention
  50. 3D culture systems as models for solid tumors and cancer metabolism
  51. Fucoidan from Fucus vesiculosus inhibits new blood vessel formation and breast tumor growth in vivo
  52. Magnetoliposomes Containing Calcium Ferrite Nanoparticles for Applications in Breast Cancer Therapy
  53. Direct actions of adiponectin on changes in reproductive, metabolic, and anti-oxidative enzymes status in the testis of adult mice
  54. Rational Identification of a Colorectal Cancer Targeting Peptide through Phage Display
  55. Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma – MCT1 as potential target in diffuse large B cell lymphoma
  56. Role of adiponectin as a modulator of testicular function during aging in mice
  57. Synthesis, characterization and in vitro validation of a magnetic zeolite nanocomposite with T2-MRI properties towards theranostic applications
  58. Photodynamic Therapy at Low-Light Fluence Rate: in vitro Assays on Colon Cancer Cells
  59. Exploitation of new chalcones and 4H-chromenes as agents for cancer treatment
  60. Adenine Derivatives: Promising Candidates for Breast Cancer Treatment
  61. Bioenergetic modulators hamper cancer cell viability and enhance response to chemotherapy
  62. The clinicopathological significance of monocarboxylate transporters in testicular germ cell tumors
  63. Internalization studies on zeolite nanoparticles using human cells
  64. Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells
  65. Impact of mesenchymal stem cells’ secretome on glioblastoma pathophysiology
  66. Alginate hydrogel improves anti-angiogenic bevacizumab activity in cancer therapy
  67. Monocarboxylate transporter 1 is a key player in glioma-endothelial cell crosstalk
  68. GLUT1 expression in pediatric adrenocortical tumors: a promising candidate to predict clinical behavior
  69. Value of pH regulators in the diagnosis, prognosis and treatment of cancer
  70. Comparison of different silica microporous structures as drug delivery systems for in vitro models of solid tumors
  71. HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors
  72. Characterization of acetate transport in colorectal cancer cells and potential therapeutic implications
  73. The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF V600E mutation
  74. Significance of glycolytic metabolism-related protein expression in colorectal cancer, lymph node and hepatic metastasis
  75. The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside
  76. Hypoxia-mediated upregulation of MCT1 expression supports the glycolytic phenotype of glioblastomas
  77. Antitumor Properties of Honeybee Plant-Derived Products: Honey, Propolis and Pollen
  78. Prognostic significance of monocarboxylate transporter expression in oral cavity tumors
  79. Lactate Transporters and pH Regulation: Potential Therapeutic Targets in Glioblastomas
  80. The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4
  81. Absence of microsatellite instability andBRAF(V600E) mutation in testicular germ cell tumors
  82. Metabolic coupling in urothelial bladder cancer compartments and its correlation to tumor aggressiveness
  83. Colon Cancer Chemoprevention by Sage Tea Drinking: Decreased DNA Damage and Cell Proliferation
  84. Targeting Metabolic Reprogramming as an Anti- Cancer Strategy: Aiming at Monocarboxylate Transporters
  85. Metabolic reprogramming: a new relevant pathway in adult adrenocortical tumors
  86. Hotspot TERT promoter mutations are rare events in testicular germ cell tumors
  87. Reprogramming energy metabolism and inducing angiogenesis: co-expression of monocarboxylate transporters with VEGF family members in cervical adenocarcinomas
  88. Glucose addiction in cancer therapy: advances and drawbacks
  89. Monocarboxylate transport inhibition potentiates the cytotoxic effect of 5-fluorouracil in colorectal cancer cells
  90. A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy
  91. Abstract B24: Natural withanolides: A new group of anticancer drugs that selectively target the PI3K-mTOR pathway as novel potent therapeutics against colon cancers in vitro and in vivo
  92. Cathepsin D protects colorectal cancer cells from acetate-induced apoptosis through autophagy-independent degradation of damaged mitochondria
  93. SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3
  94. The cytotoxicity of 3-bromopyruvate in breast cancer cells depends on extracellular pH
  95. Brain Tumor Metabolism — Unraveling Its Role in Finding New Therapeutic Targets
  96. Impact of an Educational Hands-on Project on the Antimicrobial, Antitumor and Anti-Inflammatory Properties of Plants on Portuguese Students’ Awareness, Knowledge, and Competences
  97. Micro- and Mesoporous Structures as Drug Delivery Carriers for Salicylic Acid
  98. Localization of MCT 2 at peroxisomes is associated with malignant transformation in prostate cancer
  99. In vitro and in vivo studies of temozolomide loading in zeolite structures as drug delivery systems for glioblastoma
  100. Urothelial bladder cancer progression: lessons learned from the bench
  101. Evolving hallmarks in urothelial bladder cancer: unveiling potential biomarkers
  102. Propolis: A Complex Natural Product with a Plethora of Biological Activities That Can Be Explored for Drug Development
  103. Antitumoural and antiangiogenic activity of Portuguese propolis in in vitro and in vivo models
  104. Lactate Transporters in the Context of Prostate Cancer Metabolism: What Do We Know?
  105. Lactate transporters and vascular factors in HPV-induced squamous cell carcinoma of the uterine cervix
  106. The basal epithelial marker P-cadherin associates with breast cancer cell populations harboring a glycolytic and acid-resistant phenotype
  107. CD147 and MCT1-potential partners in bladder cancer aggressiveness and cisplatin resistance
  108. T-box Transcription Factor Brachyury Is Associated with Prostate Cancer Progression and Aggressiveness
  109. A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer
  110. Characterization of monocarboxylate transporters (MCTs) expression in soft tissue sarcomas: distinct prognostic impact of MCT1 sub-cellular localization
  111. Characterization of monocarboxylate transporter activity in hepatocellular carcinoma
  112. Gene Disruption Using Zinc Finger Nuclease Technology
  113. Potentiation of 5-fluorouracil encapsulated in zeolites as drug delivery systems for in vitro models of colorectal carcinoma
  114. Differential sensitivities to lactate transport inhibitors of breast cancer cell lines
  115. Loss of caveolin-1 and gain of MCT4 expression in the tumor stroma: Key events in the progression from an in situ to an invasive breast carcinoma
  116. Portuguese propolis disturbs glycolytic metabolism of human colorectal cancer in vitro
  117. Assessing the Impact of a School Intervention to Promote Students’ Knowledge and Practices on Correct Antibiotic Use
  118. Cancer cell bioenergetics and pH regulation influence breast cancer cell resistance to paclitaxel and doxorubicin
  119. Contribution of Monocarboxylate Transporters to the Aggressive Phenotype of Breast Cancer
  120. NIR Triggered Upconversion Nanoparticle Based Drug Delivery Systems for Photodynamic Therapy
  121. A Hospital Based Cohort Study of Colorectal Cancer Cases Treated at Braga Hospital, Northern Portugal
  122. The Monocarboxylate Transporter Inhibitor α-Cyano-4-Hydroxycinnamic Acid Disrupts Rat Lung Branching
  123. Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets
  124. Zeolite Structures Loading with an Anticancer Compound As Drug Delivery Systems
  125. Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer
  126. CD147 immunohistochemistry discriminates between reactive mesothelial cells and malignant mesothelioma
  127. Lactate-Induced IL-8 Pathway in Endothelial Cells--Letter
  128. Role of monocarboxylate transporters in human cancers: state of the art
  129. Butyrate activates the monocarboxylate transporter MCT4 expression in breast cancer cells and enhances the antitumor activity of 3-bromopyruvate
  130. Co-expression of monocarboxylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low survival in patients with gastrointestinal stromal tumors (GISTs)
  131. CD147 overexpression allows an accurate discrimination of bladder cancer patients’ prognosis
  132. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer
  133. Encapsulation of α-cyano-4-hydroxycinnamic acid into a NaY zeolite
  134. Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies
  135. Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma
  136. The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment
  137. Expression of Monocarboxylate Transporters 1, 2, and 4 in Human Tumours and Their Association with CD147 and CD44
  138. Portuguese students' knowledge of antibiotics: a cross-sectional study of secondary school and university students in Braga
  139. The prognostic value of CD147/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer
  140. Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma
  141. Increasing Expression of Monocarboxylate Transporters 1 and 4 Along Progression to Invasive Cervical Carcinoma
  142. 378 POSTER CD147 expression correlates with monocarboxylate transporters 1 and 4 in cervical carcinoma
  143. Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer
  144. Induction of COX-2 expression by acrolein in the rat model of hemorrhagic cystitis
  145. Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas
  146. A New Model of Laryngitis: Neuropeptide, Cyclooxygenase, and Cytokine Profile
  147. Peritumoural, but not intratumoural, lymphatic vessel density and invasion correlate with colorectal carcinoma poor-outcome markers
  148. Lymphatic vessel density and epithelial D2-40 immunoreactivity in pre-invasive and invasive lesions of the uterine cervix
  149. Cyclooxygenase-2 expression on ifosfamide-induced hemorrhagic cystitis in rats
  150. Cyclooxygenase-2 and Epidermal Growth Factor Receptor Expressions in Different Histological Subtypes of Cervical Carcinomas
  151. Immunohistochemical expression and distribution of VEGFR-3 in malignant mesothelioma
  152. Functional Purification of the Monocarboxylate Transporter of the Yeast Candida utilis
  153. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas
  154. Functional expression of the lactate permease Jen1p of Saccharomyces cerevisiae in Pichia pastoris
  155. l–[U–14C]Lactate binding to a 43 kDa protein in plasma membranes of Candida utilis